The present invention relates to an antibody capable of binding with highaffinity and high selectivity to the ectodomain of the transmembrane proteoglycan (PG) NG2/CSPG4. The invention specifically refers to said antibody possessing the ability to uniquely induce programmed cell death through canonical caspase-dependent apoptosis or authophagy, 5 in cancer cells specifically expressing such protein, and without the participation of other exogenously added factors. Moreover, the present invention refers to a composition comprising the antibody of the invention as pharmaceutical excipients.
Titolo: | Pro-apoptotic anti-NG2/CSPG4 antibodies and their uses in disease therapy |
Autori: | |
Data di pubblicazione: | 2016 |
Abstract: | The present invention relates to an antibody capable of binding with highaffinity and high selectivity to the ectodomain of the transmembrane proteoglycan (PG) NG2/CSPG4. The invention specifically refers to said antibody possessing the ability to uniquely induce programmed cell death through canonical caspase-dependent apoptosis or authophagy, 5 in cancer cells specifically expressing such protein, and without the participation of other exogenously added factors. Moreover, the present invention refers to a composition comprising the antibody of the invention as pharmaceutical excipients. |
Handle: | http://hdl.handle.net/11381/2891268 |
Appare nelle tipologie: | 5.1 Brevetto concesso |
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.